Literature DB >> 23851700

Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis.

Akinori Miyazono1, Jun Abe, Masao Ogura, Mai Sato, Takuya Fujimaru, Koichi Kamei, Shuichi Ito.   

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory cytokine-related disorder associated with overproduction of interleukin (IL)-6, IL-1β, and IL-18. Macrophage activation syndrome (MAS) is a critical and lethal complication of sJIA. Therefore, prompt induction of remission in the active phase of sJIA is important for prevention of MAS. However, treatment of corticosteroid-resistant sJIA is still challenging. We propose a new strategy to induce remission in the active phase of sJIA. A 7-year-old boy with new-onset sJIA was treated with oral prednisolone, methylprednisolone pulse therapy, and parenteral cyclosporine, but he continuously showed remittent high fever, arthralgia, skin rash, and elevation of inflammatory markers, including hyperferritinemia. Because of impending MAS, plasma exchange was started, but he was resistant to plasma exchange. Therefore, we combined leukocytapheresis with PE. After five PE and two leukocytapheresis sessions, he finally achieved remission in accordance with a reduction in inflammatory cytokines. Elevated serum tumor necrosis factor-α, interferon-γ, and IL-12 levels returned to normal 10 days after initiating plasma exchange combined with leukocytapheresis, with a reduction in white blood cell count. In conclusion, plasma exchange combined with leukocytapheresis is a new alternative option to induce remission for patients with methylprednisolone pulse therapy- or cyclosporine-refractory sJIA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851700     DOI: 10.1007/s00431-013-2093-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

2.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

Authors:  A Ravelli; F De Benedetti; S Viola; A Martini
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

Review 3.  Interleukin-18 regulates both Th1 and Th2 responses.

Authors:  K Nakanishi; T Yoshimoto; H Tsutsui; H Okamura
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.

Authors:  T Hidaka; K Suzuki; M Kawakami; M Okada; K Kataharada; T Shinohara; M Takamizawa-Matsumoto; F Ohsuzu
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

5.  Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Tohru Nakahata; Koichi Suzuki; Etsuro Ito
Journal:  Clin Rheumatol       Date:  2006-03-25       Impact factor: 2.980

6.  Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.

Authors:  T Hidaka; K Suzuki; Y Matsuki; M Takamizawa-Matsumoto; K Kataharada; T Ishizuka; M Kawakami; H Nakamura
Journal:  Arthritis Rheum       Date:  1999-03

7.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis.

Authors:  Kunihiko Umekita; Toshihiko Hidaka; Shiro Ueno; Ichiro Takajo; Yasufumi Kai; Yasuhiro Nagatomo; Akira Sawaguchi; Tatsuo Suganuma; Akihiko Okayama
Journal:  Mod Rheumatol       Date:  2009-04-01       Impact factor: 3.023

9.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

10.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Hermine I Brunner; Pierre Quartier; Tamás Constantin; Nico Wulffraat; Gerd Horneff; Riva Brik; Liza McCann; Ozgur Kasapcopur; Lidia Rutkowska-Sak; Rayfel Schneider; Yackov Berkun; Inmaculada Calvo; Muferet Erguven; Laurence Goffin; Michael Hofer; Tilmann Kallinich; Sheila K Oliveira; Yosef Uziel; Stefania Viola; Kiran Nistala; Carine Wouters; Rolando Cimaz; Manuel A Ferrandiz; Berit Flato; Maria Luz Gamir; Isabelle Kone-Paut; Alexei Grom; Bo Magnusson; Seza Ozen; Flavio Sztajnbok; Karine Lheritier; Ken Abrams; Dennis Kim; Alberto Martini; Daniel J Lovell
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

View more
  1 in total

1.  A high-throughput microfluidic device based on controlled incremental filtration to enable centrifugation-free, low extracorporeal volume leukapheresis.

Authors:  Dalia L Lezzar; Fong W Lam; Ravin Huerta; Anton Mukhamedshin; Madeleine Lu; Sergey S Shevkoplyas
Journal:  Sci Rep       Date:  2022-08-13       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.